Ibnsina Pharma results, Q1 2024
Net profit, assets, equity and cash flow for Q1 2024, against the same period a year earlier, from the published financial statements.
Net profit98.14 millionEGP · +35.3% vs the same period a year earlier
Total assets20.66 billionEGP · +34.8% vs the same period a year earlier
Shareholders' equity1.55 billionEGP · +16.1% vs the same period a year earlier
Operating cash flow-396 millionEGP · +27.0% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q1 2024 was about 98.14 million EGP, up +35.3% from 72.55 million EGP in Q1 2023.
- Total assets at the end of Q1 2024 were about 20.66 billion EGP, and shareholders' equity about 1.55 billion EGP.
- Operating cash flow for Q1 2024 was negative at 396 million EGP.
Key lines against the same period a year earlier
This periodQ1 2023Change
Net profit98.14 million72.55 million+35.3%
Gross profit811 million575 million+41.2%
Total assets20.66 billion15.32 billion+34.8%
Total liabilities19.11 billion13.99 billion+36.6%
Shareholders' equity1.55 billion1.33 billion+16.1%
Total liabilities and equity20.66 billion15.32 billion+34.8%
Operating cash flow-396 million-542 million+27.0%
Investing cash flow-58.29 million-52.53 million−11.0%
Financing cash flow265 million621 million−57.3%
Net change in cash-188 million26.41 million−813.7%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy